DRAXIMAGE® I-131 Therapeutic Solution

The leading manufacturer and supplier of radioactive iodine (I-131) in the US and Canada, Jubilant DraxImage is committed to ensuring health care professionals have access to this important medication so they can provide high-quality care to their patients with thyroid cancer or hyperthyroidism.

TX-SOLUTION

How DRAXIMAGE® I-131 Therapeutic Solution Works

The thyroid gland needs iodine to produce its essential hormones that help regulate the body’s metabolism. The hormones the thyroid produces are called T3 (triiodothyronine), T4 (thyroxine), and calcitonin. The thyroid is remarkably efficient in capturing and storing iodine from one’s diet. Radioactive iodine, such as iodine-131, is captured by the thyroid in the same way. However, when iodine-131 accumulates in thyroid cells, it releases radiation that will destroy these cells. This unique ability has made iodine-131 a preferred treatment option for differentiated thyroid cancer (DTC), the most common form of thyroid cancer, and hyperthyroidism.

DRAXIMAGE® I-131 Therapeutic Solution is typically used in the following scenarios as part of DTC treatment:1

  • Ablation—Destroys normal thyroid tissue following surgery
    • Facilitates long-term monitoring of any progression or spread of cancer2
    • Enhances the effectiveness of future radioiodine treatments, if needed, by allowing delivery of higher doses2
  • Adjunct therapy—Detects and destroys suspected residual disease and distant metastases
    • Minimizes risk of DTC relapse or recurrence
  • Treatment of recurrent thyroid cancer

Product Overview

Product Name

Sodium Iodide I 131 Solution, USP Therapeutic – For Oral Use

Indications

Sodium iodide I-131 solution is indicated for the treatment of hyperthyroidism (diffuse toxic goiter and single or multiple toxic nodular goiter). It may also be used for the treatment of recurrent hyperthyroidism after surgery.

Sodium iodide I-131 capsule may also be used for therapy of some thyroid carcinomas such as functioning metastatic papillary or follicular carcinoma of the thyroid.

Description

Aqueous solution containing sodium iodide I-131 for therapeutic use by oral administration.

Note

The solution is available containing the desired quantity of I-131 calibrated for the required date. The specific activity of Iodine-131 is designated as no-carrier-added. Note: the available minimum activity is 111 MBq (3 mCi) per vial and the maximum activity is 7400 MBq (200 mCi) per vial.

Product Monograph

Click to view Product Monograph

MSDS

Click to view MSDS

Reference:

  1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
  2. Van Nostrand D. I131 ablation and treatment in well differentiated thyroid cancer. In: Van Nostrand D, Bloom G, Wartofsky L, Kulkarni KP, eds. Thyroid Cancer: A Guide for Patients. Pasadena, MD: Keystone Press; 2004;201-203.

DISCLAIMER:

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.